Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA

Angelo de Claro named acting director of FDA Oncology Center of Excellence

Angelo de Claro was named acting director of the FDA Oncology Center of Excellence, following Richard Pazdur’s departure from that position—and the agency (The Cancer Letter, Dec. 5, 2025).

Cedars-Sinai researchers develop risk score to help predict pancreatic cancer recurrence

Cedars-Sinai investigators, leading a multi-institutional team, have developed and validated a tool to predict which patients with pancreatic neuroendocrine tumors need closer monitoring because their cancer is more likely to recur.

December 19, 2025

Vol.51 No.46

Drugs & Targets

FDA grants regular approval to rucaparib for metastatic castration-resistant prostate cancer

FDA has approved rucaparib (Rubraca) for adults with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer previously treated with an androgen receptor-directed therapy.

December 19, 2025

Vol.51 No.46

Drugs & Targets

FDA and OS Therapies hold Type C meeting regarding phase IIb clinical trial of OST-HER2 in the prevention or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma

FDA and OS Therapies held a Type C meeting regarding the phase IIb human clinical trial of OST-HER2 in the prevention or delay of recurrent, fully-resected, pulmonary metastatic osteosarcoma.

December 19, 2025

Vol.51 No.46

Drugs & Targets

FDA awards National Priority Voucher to Tecvayli+Darzalex based on phase III study results

FDA has awarded a National Priority Voucher to teclistamab (Tecvayli) in combination with daratumumab (Darzalex) for relapsed/refractory multiple myeloma. This brings the total number of products receiving an award under the Commissioner’s National Priority Voucher pilot program to 16.

December 19, 2025

Vol.51 No.46

Podcast

Testing for asbestos in talc-based cosmetics seems like a no-brainer—why did FDA withdraw a rule to standardize it?

Last month, FDA withdrew a proposed rule for standardized asbestos testing in talc-based cosmetics. The proposed rule, introduced in Nov. 2024 and withdrawn Nov. 2025, was mandated by the Modernization of Cosmetics Regulation Act of 2022 or MoCRA.

December 17, 2025

Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA

YOU MAY BE INTERESTED IN

Angelo de Claro named acting director of FDA Oncology Center of Excellence

Cedars-Sinai researchers develop risk score to help predict pancreatic cancer recurrence

FDA grants regular approval to rucaparib for metastatic castration-resistant prostate cancer

FDA and OS Therapies hold Type C meeting regarding phase IIb clinical trial of OST-HER2 in the prevention or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma

FDA awards National Priority Voucher to Tecvayli+Darzalex based on phase III study results

Testing for asbestos in talc-based cosmetics seems like a no-brainer—why did FDA withdraw a rule to standardize it?

Renew today!

Subscriber content

Never miss an issue!

Login